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1 INTRODUCTION 
Rational use of drugs means that patients receive medications appropriate to 
their clinical needs, in doses that meet their own individual requirements, for 




In general terms rational pharmacotherapy is worldwide accepted concept, 
relevant to European countries also. Among essential principles of rational 
pharmacotherapy still belongs evidence-based drug. It is crucial in transfer of 
knowledge from clinical research outcomes to clinical practice. Another 
principle is to search out and used only credible data and information. Created 
according guidelines and standards arise from condition of clinical practice. 
Major sense has health technology assessment process. This process describes 
procedure about attestation of efficacy, safety, and cost-effectiveness.
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Despite medical and technological advances, that have produced hundreds of 
drugs that are safe and effective against bacteria, viruses, fungi and parasites, 
infectious diseases are still a major cause of death, disability and social and 
economic problems around the world. 
Tendency of work was chart range of adherence to created national guidelines. 
Further gain all available data about the patients from whole period of their 
treatment due to infection disease, which are important for description of 
patterns in prescribing of antibiotics. 
The aim of theoretical part of research was to study the principles and 
recommendations for rational antibioticotherapy (both treatment and 
prophylaxis) together with survey of descriptions about pharmaceutical care of 
patients with renal replacement therapy. 
The aim of practical part was evaluation of all cases of antibiotic therapy in 
KMUK (Clinic of Kaunas Medical University) for patients treated with dialysis 
in out-patients settings during two years 2005 and 2006, compare adherence to 
national guidelines among two years and among two out-patient settings (in 
dialysis and in general practice) and look for tendencies in antibiotic pre-
2 
scriptions practices. Finally, perform the analysis of possible reasons of non-
adherence for antibiotic prescriptions that considered as non-adherent. 
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2 LITERATURE SEARCH 
2.1 Concept of Rationality 
Each nation has to establish its own drug policy, within its own political and 
economic realities and in the light of its own problems and possibilities. The 
choice made reflects its social values and culture. Although the goals of 
national drug policy may differ according to countries, some core objectives 
have been defined which can be summarized as follows: to make effective, 
safe, low-cost drugs of quality available to meet the needs of the entire 
population (so called “essential drugs”); to ensure that all drugs are used 
rationally; and to develop the overall development strategy of country.
3
 
2.1.1 Rationality in pharmacotherapy 
Rational pharmacotherapy (RPT) is conception defining principles, funda-
mentals and the rules of selection of interventions.
4
 By this question consider 
pharmaceutical care (differ from traditional drug treatment), because it is 
explicitly outcome-orientated co-operative, systematic approach to provide 
drug therapy directed not only at clinical outcomes, but also at activities of 
daily life and other dimension of health-related quality of life.
5
 Goals of 
therapy are necessary in order to produce and document positive outcomes. For 
each medical condition health care provider and the patient must agree upon 
clear and concise goals of therapy. Establishing goals of therapy is an essential 
step toward ensuring a patient will maximally benefit from drug therapies.
27
 
2.1.2 The process of rational therapy 
Rational therapy requires a logical approach and common sense, based on 
efficacy, safety, suitability, and cost. Prescribing should be part of a logical 
deductive process, based on comprehensive and objective information. It 
should not be a reflex, a recipe a “cook-book, or a response to commercial 
pressure. A good scientific experiment follows a rather rigid methodology with 
a definition of the problem, a hypothesis, an experiment, an outcome and a 
process of verification. This process, and especially the verification step, 
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ensures that outcome is reliable. The same principles are applied by treating a 
patient. First is necessary to define carefully the patient’s problem (the 
diagnosis). After that, the demand is to specify the therapeutic objective, and to 
choose a treatment of proof efficacy and safety, from different alternatives. 
Next proceeding is writing an accurate prescription and providing the patient 
with clear information and instruction. After some time the results of the 
treatment should be monitor, only then procedure has been successful. If the 
problem has been solved, the treatment can be stopped. If not, it would need to 
re-examine all steps. 
Choosing a treatment has two important stages. It starts by considering the 
“first-choice” treatment, which is the result of a selection process done earlier. 




2.1.3 Specificity in antibiotic therapy 
The simultaneous use of multiple antibiotics in a shotgun should be avoided 
because of the problems of drug toxicity and sensitisation, microbial superin-
fections, and antagonism between certain agents. Most bacterial infection can 
be treated satisfactorily with a single antimicrobial agent. There are a limited 
number of situations, however, in which simultaneous administration of 
chemotherapeutic agents is warranted: 
1. synergism between two antimicrobials against a specific infecting agent 
2. prevention of emergence of resistance to one or both drugs 
3. treatment of polymicrobial infections for which one antibiotic is not 
sufficient 
4. initial treatment of life-threatening infections before isolation of 
etiologic agent 
Although the choice of antimicrobial drugs must be always individualized, 
there are useful guidelines that can be followed.
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2.1.4 General guidelines in antibioticotherapy 
The essential feature of effective chemotherapeutic agents is ability to inhibit 
microorganisms at concentration tolerable by the host. The most successful 
5 
antimicrobial agents are those that target anatomic structures or biosynthetic 
functions unique to microorganism. 
The appropriate choice of chemotherapy for an infection depends on five 
considerations: 
1. the infecting organism and its antimicrobial susceptibilities 
2. the type of infection (e.g., bacteraemia, urinary tract infection) 
3. host factors (e.g., neutropenia, concurrent illness, age, renal function) 
4. the antimicrobial agents (e.g., dosage, routes of administration, drug 
interaction, potential toxicities, cost) 
5. public health considerations 
The wide spread use of antibiotics select highly resistant organism that sub-




2.2.1 General principles of antibiotic selection 
The selection of appropriate antibiotic therapy depends on a number of impor-
tant factors. First, antibiotics are useful only for the treatment of bacterial in-
fections, and so general confirmation of the presence of such an infection is 
critical. As general rule, whenever possible appropriate clinical specimen 
should be obtained to attempt a culture-proven diagnosis so that the most effec-
tive antibiotics can be selected for targeted therapy and for correct duration.
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2.2.2 Infecting organism 
Prompt identification of the causative organism is essential for the selection of 
appropriate antimicrobial drugs. Culture identifications of the infecting 
organism can offer a clue to the likely antimicrobial susceptibilities. Another 
necessary point is determination of the in vitro susceptibility of isolated bac-
teria. 
The efficacy of antibiotic therapy depends of delivery to the site of infection. 
Transport across the blood-brain barrier varies considerably among antibiotics. 
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2.2.3 Route of administration 
Concerning the route of administration many antibiotics are absorbed 
sufficiently well via the oral route to provide effective blood levels in patients 
with normal gastrointestinal function. The enteral absorption of some antimi-
crobials is impeded by food and some medication. Many antibiotics cannot be 
given intramuscularly because of the local pain or necrosis at the injection site. 
Intravenous administration must be used in treatment of major and life-threa-
tening infections such as septic shock meningitis, pneumonia, and endocarditis. 
In many cases, patients are clinically stable during intravenous treatment, and 
it is often possible to discharge them and to administer parenteral antibiotics 
on an outpatient’s basis. 
2.2.4 Concurrent illnesses 
Patients with immunosuppressive illnesses are vulnerable to opportunistic 
pathogens. These patients may require broader antimicrobial coverage as well 
as intense therapy for ordinary pathogens. The same is true to a lesser extent 
for patients with chronic debilitating illness. Patients with renal insufficiency 
or liver disease may be unusually susceptible to direct toxicity. 
Many antimicrobial agents (e.g., penicillins, cephalosporins, aminoglycosides, 
vancomycin, and fluoroquinolones) are excreted by the kidney. Dosage adjust-
ment in patients who have severe renal failure and are undergoing dialysis or 





Antimicrobial chemoprophylaxis refers to the use of antibiotics for preventing 
infection either before or very shortly after introduction of pathogenic orga-
nism (for example, after the occurrence of a compound fracture but before the 
appearance of clinical infection). Chemoprophylaxis is most effective when a 
specific drug is selected for its activity against particular organism. When pro-
phylaxis is aimed at preventing all possible organisms from initiating infection 
may occur it is likely to be unsuccessful, because it only selects out the most 
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drug-resistant organism as the cause of any infection that follows. Most uses of 
chemoprophylaxis fall into three general categories: prevention of infection 
after exposure to a specific pathogen, prevention of specific types of infection 
highly susceptible individuals, and prevention of postoperative complications. 
In many instances, prophylactic use of antimicrobial agents is widely practiced, 
but convincing data validating the efficacy of this approach are not available
8
. 
The use of antimicrobial prophylaxis in surgery involves a risk-to-benefit 
evaluation that varies depending on the nature of the operative procedure. To 
help wound infection in patients undergoing elective surgery, antibiotics should 
be administered within two hours before the incision made. If prophylactic 
antibiotics are to be effective, administration should be timed so that thera-
peutic levels are attained at surgery, but selection of bacteria resistant to the 




The prevention of surgical site infection remains a focus of attention because 




2.3 Therapeutic area 
2.3.1 Infections in the dialysis patients  
In our daily life we are surrounded by a wealth of microorganisms, the majority 
of which are inoffensive.
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In dialysis patients, there is impairment of several aspects of lymphocyte and 
granulocyte function. Bacterial infections occur more often in these patients 
than in their counterparts; the increase is probably related more to the frequent 
violation of normal skin and mucosal barriers than to the immune system 
dysfunction. Also we can discover more seriousness in infections and resolve 
less promptly than in nonuremic patients. Another division of bacterial 
infection may be according access site. 
Access site infections related to the access site are the source of 50-80% of 
bacteremias. The infection rate of permanent AV fistulas is lower than with 
AV grafts. Generally clinical manifestations of bacteremia are chills, fever, 
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redness, and tenderness. Delayed treatment of sepsis in dialysis patients is an 
important cause of morbidity and mortality. In a recent study (Marr et al, 
1997), 40% of catheter-treated patients developed at least one episode of 
bacteremia over a 9 months period. 
Into the second, unrelated to the access site, belong urinary tract infections, 
especially those with polycystic kidney disease. Further are respiratory tract 
infections, mainly pneumonia, which is an important cause of mortality in this 
population. We can mention intra-abdominal infections like a diverticulosis 
and diverculitis. The incidence of tuberculosis has been estimated to be as 
much as 10-fold higher among hemodialysis patients than among general 
population. Specifications of next infections are septicemia caused by Salmo-
nella, Helicobacter pylori infections, and listeriosis.
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Pulmonary infections span a wide spectrum, ranging from self-limited pro-
cesses to life-threatening infections and from acute illness to chronic infla-
mmatory diseases. The widespread use of antimicrobial agents has led to the 
emergence of drug-resistant strains; thereby altering and expanding the range 
of pathogens are responsible for pneumonia, especially in hospitalized 
patients.
7
 The causes of community-acquired pneumonia are Streptococcus 
pneumoniae and then Haemophilus influenza. The so-called atypical pneumo-




Urinary tract infections are further one of the most common bacterial 
infectious diseases. Depending on the localization and the effectiveness of 
pathogenetic factors, various clinical pictures (lower urinary tract infection, 
pyelonephritis, asymptomatic bacteriuria) have to be differentiated. There are 
virulence factors of microorganisms on the one hand and defense mechanisms 
on the other, which influence the manifestation and the course of disease.
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 In 
nephrology patients are the most common acute and chronic pyelonephritis. 
Acute pyelonephritis also must be distinguished from chronic pyelonephritis, 





Skin associated kind of infection in these patients is “A-V” fistula infections. 
Even with excellent placement technique, bacteria can enter the bloodstream 
directly through the catheter during dialysis. Bacteria from the skin can also 
move down the catheter and enter the bloodstream. Generally physicians must 
remove the catheter so the body can fight with the infection. 
2.3.1.1 Principles of drug therapy in patients with renal disease 
Patients with reduced renal function commonly require drugs therapy for 
various associated conditions. Most drugs are fully or partially excreted by 
kidney. Therefore dosage regimen often needs to be adjusted for order to 
provide safe yet effective treatment for patients with renal disease. In addition, 
certain therapeutic agents have potential nephrotoxicity and pharmacologic 
action that may endanger already reduced renal function. Understanding of 
drugs pharmacology, the therapeutic doses and speed of drug elimination in a 
given patients will lead to correct assessment of drug regimen. 
2.3.2 Chronic renal failure 
Chronic renal failure (CRF) may be defined as a condition characterized by 
uraemia, acidosis, osteodystrophy, neuropathy, and general debility frequently 
accompanied by hypertension, oedema and susceptibility to infection resulting 
from significant reduction in the excretory, homeostatic metabolic and endo-
crine functions of the kidney that occur over a period of months or years. The 
symptoms of CRF generally manifested when the glomerular filtration rate has 
fallen to about 15 ml/min. 
Chronic renal disease generally progresses through four stages: 
1. renal reserve reduction 
2. renal insufficiency 
3. CRF 
4. end-stage renal failure (ESRF) 
Reduction in renal reserve 
The kidney usually has greater capacity to function than is required under nor-
mal conditions. This extra capacity is termed “renal reserve”. In the early sta-
ges of chronic renal disease, damage to kidney eradicates this response for con-
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ditions that place additional demands upon the kidney, such as pregnancy or in-
creased dietary protein, cannot adequately be met. 
Renal insufficiency  
In this stage, toxins such as creatinine and urea that are normally excreted by 
the kidney begin to accumulate, although electrolyte levels often remain within 
normal limits as a result of homeostatic adaptations. Compensation will 
unavoidably result in imbalances elsewhere, such as acidaemia, bone disease, 
and changes in hormone level, for example parathyroid hormone. 
Chronic renal failure 
A progressive decline in renal function produces a wide range of both bio-
chemical and hormonal abnormalities. Symptoms may still be insignificant 
despite severe disturbance of homeostasis. 
End stage of renal failure 
ESRF is characterized by uraemia and wide spectrum of gastrointestinal, 
dermatological and CNS symptoms. End-stage kidney disease occurs when the 
kidneys are no longer able to function at a level that is necessary for day to day 
life. It usually occurs as chronic renal failure worsens to the point where kidney 
function is less than 10% of normal.
14
 
2.3.2.1 Incidence and causes 
Accurate information on the incidence of CRF is difficult to obtain but some 
data are available from community – based studies and registries of patients 
entering renal replacement programmes. The incidence of CRF in men is at 
least 1,5 times greater than in women and this difference becomes more pro-
nounced with age. The increasing incidence of CRF with age is attributable to 
non – immunological causes including vascular disease and undiagnosed 
prostatic disease in men. There are also racial differences in the incidence 
of Afro – Caribbean and Asian population in comparison with comparable 
white population. These differences might result from greater severity of 
hypertension in Afro – Caribbeans and diabetic nephropathy in Asian groups, 
but other factor, such as social deprivation may also contribute. 
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The reduction in renal function observed in CRF results from damage to the 
infrastructure of the kidney. It is thought nephrons are lost as complete units 
with all functions lost simultaneously. The remaining nephrons cope initially 
with the increase demand upon them. The patient remains well until so many 
nephrons are lost that the glomerular filtration rate can no longer be maintained 
despite activation of compensatory mechanisms. As consequence the GFR 
progressively declines. The patients may well remain symptom free until the 
GRF falls as low 15-20 ml/min. 
CRF arises from a variety of causes (e.g., chronic glomerulonephritis, pyelo-
nephritis, diabetes, polycystic kidney disease, and other). The difficulty in 
establishing a diagnosis of CRF increases in patients aged over 65, However, 
establishing a cause is useful in the identification and elimination of reversible 
factors, in planning for likely out comes and treatment needs, and for 
appropriate counselling when a genetic bases is established. 
Chronic glomerulonephritis should not be regarded as a single disease as 
there are many forms, which may be either idiopathic or part of systemic 
disease. The precise aetiology is unknown but it is though to be mediated by 
deposition of immune complex in the glomerular tuft with subsequent 
development of an inflammatory response. Responsible antigens include 
certain strain of streptococci, other infection such as malaria, endogenous 
antigens from, for example neoplastic lesions, DNA, for example in systemic 
lupus erythematosus, and certain drugs, including non – steroidal anti –
 inflammatory agents, gold, and penicillamine. 
Hypertension is both a common result and a frequent cause of CRF. It may be 
prevented by adequate treatment, thereby preventing a further decline in renal 
function. 
Chronic pyelonephritis refers to chronic inflammation of the renal 
parenchyma with scarring of the kidney. It is generally caused by recurrent 
urine infection, which may be secondary to outflow obstruction or reflux 
nephropathy. 
Metabolic diseases, where the most common is diabetes mellitus may lead to 
chronic glomerulonephritis. 
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Urinary obstruction may develop insidiously and the classical symptom of 
oliguria or pain may even be absent. Causes include prostate hypertrophy, renal 
calculi, congenital abnormalities, vesicoureteric reflux. 
Interstitial nephritis is caused by inflammation of the interstitium of the 
kidney with secondary involvement of the tubules is often effected by toxins. 
Drugs such as penicillin, analgesics, and diuretics are typical toxins. Interstitial 
nephritis is more common in those patients aged over 65, possibly because 
people in this group are prescribed greater number of drugs. 
The principle congenital abnormality encountered is adult polycystic kidney 
disease. This is an autosomal dominant inherited condition which results in the 
formation of multiple cysts in both kidneys throughout life. The kidneys 
become enlarged and frequently fail in middle age. 
2.3.2.2 Diagnosis, investigations, and monitoring 
The diagnosis may be suspected because of signs and symptoms of renal 
disease. More often CRF is discovered during investigation of other medical 
problems or following other routine screening. 
Family, drug and society histories are all important in elucidating the causes of 
renal failure, since genetic or exposure to toxins, including prescription, over –
 the – counter and herbal drug, might be implicated. 
The history of CRF often includes a long of period of polyuria (excessive urine 
production), usually with nocturia (walking at night to pass urine). The sym-
ptoms of uraemia are usually non-specific and include lethargy, breathlessness, 
anorexia, and nausea. When these symptoms occur they are often exacerbated 
by anaemia resulting from a reduction in erythropoetin production. Other 
anamnestical symptoms include an excruciating itch, poor sleep patterns, and 
lack of concentration and “restless leg” that may be particularly troublesome at 
night. Patients may also present with pigmented skin or hypertension. 
Functional assessment of kidney may be performed by testing serum and urine. 
The serum creatinine level is more reliable indicator of renal function then the 
serum urea level though both are normally measured. Hyperkalaemia, acidosis 
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with a correspondingly low serum bicarbonate level, hypocalcaemia, and 
hyperphosphataemia may also be present. 
Urine should be examined visually and microscopically, tested with dipstick, 
cultured and 24 hours collection made for determination of GFR. 
The patient may report a change in urine colour, which might result from blood 
staining by whole cells or haemoglobin, drugs or metabolic breakdown pro-
ducts. Urine may also appear milky after connection with lymphatics, cloudy 
following infection, contain solid material such a stones, crystal casts, or froth 
excessively in proteinuria. Dipstick test enable simple, rapid estimation of a 
wide range of urinary parameters including pH, specific gravidity, glucose, 
blood and protein. Positive results should, however, be quantified by more 
specific methods. 
Urinary creatinine excretion and the serum creatinine concentration may be 
used to calculate creatinine clearance, which approximates to GRF. As serum 
creatinine is determined partially by muscle bulk as well as renal function, 
correction for muscle mass using for patient’s weigh, age and gender yield 
estimates of the GRF from the serum creatinine. 
In some patients the kidney may be palpable. Large irregular kidneys are indi-
cative of polycystic disease, whereas smooth, tender enlarged kidneys are 
likely to be infected or obstructed. However, in most cases of CRF, the kidneys 
appear wizened. 
Structural assessment of the kidney may be performed using a number of 
imaging procedures, including: ultrasonography, intravenous autography, plain 
abdominal radiography, computed tomography, magnetic resonance imaging, 
and magnetic resonance angiography. 
2.3.2.3 Clinical manifestations 
Urinary symptoms 
Polyuria where the patients frequently voids high volumes of urine could be 
seen in CRF and results from medullary damage and the osmotic effect of high 
plasma urea levels (>8 mmol/l). The ability to concentrate urine is also lost in 
CRF, which together with failure of physiological nocturnal antidiuresis, 
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results almost invariably in nocturia, where the patients will be wakened two or 
three times a night with a full bladder. 
Proteinuria 
A degree of proteinuria invariably occurs in CRF and can result from 
glomerular leaks, infection, and failure of protein reabsorption in the tubules or 
overflow or excess plasma proteins as seen in myeloma. Pronounced protein-
uria (> 2 g of protein in 24-hour collection) usually indicates a glomerular 
etiology. 
Fluid retention 
As a GFR falls to very low levels the kidneys are unable to excrete salt and 
water adequately, resulting the retention of extra vascular fluid, which may be 
seen around the eyes on waking, the sacral region in supine patients and from 
the feet upwards in ambulatory patients. Volume dependent hypertension 
occurs in about 80% of patients with CRF and becomes more prevalent of the 
GRF falls. 
Uremia 
Many substances including urea, creatinine, and water are normally excreted 
by the kidney and accumulate as renal function decreases. Some of the 
substances responsible for the toxicity of uremia are intermediate in size 
between small, readily dialysed molecules and large non – dialysable proteins. 
These are described as “middle molecules” and include phosphate, guanidines, 
phenols, and organic acids. Clearly, there are a wide range of uremic toxins but 
it is the blood level of urea and creatinine that are often used to estimate the 
degree of toxin accumulation in uremia. 
The symptoms of uremia are many and various and include anorexia, nausea, 
vomiting, constipation, foul taste, and skin discoloration that is presumed to be 
due to pigment deposition compounded by the pallor of anemia. The 
characteristic complexion is often described as “muddy”, and is frequently 
associated with severe pruritus without an underlying rash. In extremely severe 
cases crystalline urea is deposited on the skin (uremic frost). 
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Anemia 
Anemia is an almost inevitable consequence of chronic renal failure and is 
generally noticeable when the GRF falls less than 30 ml/min (the serum creati-
nine is likely to be >300 µmol/l at this point.). The fall in hemoglobin level is a 
slow, insidious process accompanying the decline in renal function. A normo-
chronic, normocytic pattern is usually seen with hemoglobin levels falling to 
between 6 and 8 g/dl in ESRF. 
Several factors are thought to contribute to the pathogenesis of anemia in CRF, 
including shortened red cell survival, marrow suppression by uremic toxins and 
iron or folate deficiency associated with poor dietary intake or increased losses, 
for example from gastrointestinal bleeding. However, the principals cause 
result from damage of peritubular cells leading to adequate secretion of 
erythropoietin. This hormone, which is produced mainly, though not exclu-
sively, in the kidney, is the main regulator of red cell proliferation and differen-
tiation in bone marrow. Hyperparathyroidism also reduces erythropoiesis by 
damaging bone marrow and therefore exacerbate anemia associated with CRF. 
Concerning clinical findings in CRF is the major cause of fatigue, breathless-
ness at rest on exertion, lethargy, and angina often seen in patients with CRF. 
These patients will also complain of a sensation of feeling cold, poor 
concentration and reduced appetite and libido. Compensatory haemodynamic 
changes occur in patients with anemia associated with CRF. Cardiac output is 
increased to improve oxygen delivery to tissue although this may result in 
tachycardia and palpitations. As a consequence many patients cope relatively 
well with profoundly low hemoglobin concentrations but benefit from 
corrective therapy. 
Hyperparathyroidism (HPT) 
HPT not only affects the skeletal system but also other organs especially in 
combination with hyperphosphatemia. The impact on cardiovascular mortality 
in the prevalent and incident dialysis population makes prevention of HPT 
obligatory. In chronic renal failure hypocalcemia, hyperphosphatemia stimulate 
synthesis and secretion of parathyroid hormone and cellular kinetics of the 
parathyroid gland. The percentage of dialysis patients in need of 
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parathyroidectomy increases continuously with duration of dialysis treatment. 
After 15 years of treatment 40% of all patients were parathyroidectomized 
according to the EDTA-report from 1991.
15,16
 
Electrolyte disturbances  
Since the kidney play such a crucial role in the maintenance of volume, 
extracellular fluid composition and acid – base balance, it is not surprising that 
disturbances of electrolyte levels (mainly, hyperkalemia, hyponatremia, hyper-
phosphataemia and hypocalcemia) are seen in CRF. 
Hypertension and CRF changes 
The vast majority of patients with CRF will have hypertension. Furthermore, 
raised blood pressure may exacerbate renal damage and precipitate or worsen 
CRF. 
Severe renal impairment leads to sodium retention, which is turn produces 
circulatory volume expansion with consequent hypertension. This form of 
hypertension is often termed “salt-sensitive”, as it may be exacerbated by salt 
intake, or “wet”, as it results from fluid retention. Lesser degrees of renal im-
pairment reduce kidney perfusion, which activates renin production, with 
subsequent angiotensin mediated vasoconstriction. Hypertension of this form 
can be termed “salt-resistant”, as it is not generally salt sensitive, or “dry” 
hypertension owing to its dependence upon vasoconstriction may coexist under 
certain circumstances. 
Treatment of blood pressure, irrespective of choice of therapy, generally 
improves to course of CRF. Eye damage in form of hypertensive retinopathy 
may be found in these patients whose blood pressure has not been adequately 
controlled. Appropriate and timely antihypertensive therapy can help prevent 
this. 
Hemostasis 
In uremia there is also an increased tendency to bleed. This is further exacer-
bated by anemia because of impaired platelet adhesion and modified inter-




Consideration should also be given to lipid profile of the patient and where 
appropriate, treatment with HMG CoA reductase inhibitors (statins) commen-




Renal bone disease 
Renal bone disease is a composite of high- and low-turnover bone disease. In 
uremia there is skeletal resistance to the action of circulating parathyroid 
hormone PTH, and often early vitamin D deficiency. Initiative symptoms are 
very rare, so biochemical and radiological test are required. Control of plasma 
phosphate (dietary compliance, phosphate binders), correction of metabolic 
acidosis (using of sodium bicarbonate), and judicious use of vitamin D ana-
logues are needed. Over-enthusiasm however can induce low-turnover bone, 





The most common neurological changes are non-specific and include inability 
to concentrate, memory impairment, irritability and stupor probably caused by 
uremic toxins. Fits owing to cerebral oedema or hypertension may occur. Most 
patients have evidence of peripheral neuropathy, although this is usually 
asymptomatic. 
Psychiatric problems 
These problems are much more common in CRF and dialysis patients. These 
range from depression, anxiety, and phobias, to full-blown psychosis. Sym-
pathy, realism, education, and counseling are all important. Patients with 
severe mental disorders are especially challenging to manage on dialysis. 
Dialysis staff is becoming heavily stressed, when patients are rude and un-
cooperative to them. Lack of understanding, fear, and drug abuse, or undia-




Skin problems include excoriation, xerosis, nodular prurigo, pseudomyxe-
damatous scleroderma; “half-and-half” nails (gross shortening of distal 
phalanges). 
Infection rates and immune system function 
These are often abnormal in CRF. Infection is a common cause of death and 
morbidity. T – Cells function is defective, as is neutrophil activity against bac-
teria. Patients are notoriously hard to immunize. 
2.3.2.4 Clinical intervention to retard progression to end-stage 
renal failure 
Dietary manipulation has long been advocated as a means of retarding CRF. 
There are many trials. The largest of them, the MDRD (modification of diet in 
renal disease) study, followed 840 patients over 3 years and was not able to 
show differences in renal function decline between patients with and without 
dietary restriction. Re-analysis, and meta-analysis, can provide some sugges-
tion that for severe renal impairment, severe protein restriction can retard GFR 
decline. First, because of the anorectic effect of uremia, many patients self – re-
strict their total calorie (and hence protein) intake. Second, there is real damage 
in further restricting food intake in patients already prescribed a great deal. 
Blood pressure control is one of the most important therapeutic measures 
since there is a vicious cycle of events whereby hypertension causes damage to 
the intrarenal vasculature resulting in thickening and hyalinization of the walls 
of the arterioles and small vessels. Reduced renal perfusion leads to stimulation 
of the renin-angiotensin-aldosterone system. 
Antihypertensive therapy might produce a transient reduction in GRF over the 
first 3 months of treatment as the blood pressure drops. However, it is possible 
that control of blood pressure will ultimately lead to an improvement in renal 
function. This can be sufficiently dramatic that suspension of renal replacement 
therapy can occasionally be warranted in patients with ESRF. 
Recent meta-analysis for the period 1977-99 has suggested that ACE inhibitors 
provide unique nephroprotection. 
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2.3.2.5 Transition from predialysis to renal replacement 
therapy (RRT) 
One of the prime reasons for timely nephrologic referral of a patient with 
declining renal function is to facilitate an orderly start of renal replacement 
therapy. Among the goals to be achieved in this setting, uppermost are 
reducing the rate of renal function decline to a minimum, reversing/preventing 
the complication of renal disease at this stage (e.g. renal bone disease, anemia, 
acidosis, left ventricular hypertrophy), evaluation of possibility to be 
transplanted, formation of dialysis access (e.g. ventricular fistula) in good time, 
and allowing the patient and careers to be educated about renal disease, its 
implication, and treatments. 
RRT consists of dialysis or transplantation modalities. Further focus is directed 
toward dialysis treatment only. There is no precise creatinine value or GRF at 
which dialysis must be started. With careful attention to detail many patients 
can function well even with GRF values <10ml/min. In certain cases, fluid 
overload or hyperkalemia mandate a sudden start of RRT. 
2.3.3 Dialysis as a RRT 
2.3.3.1 Introduction 
Hemodialysis (HD) has evolved from certainly primitive physical arrangement 
to a computerized, mechanical maneuver. This advance however is not what it 
seems – the principles of dialysis four decades ago were substantially similar to 
those in use now. Blood needs to be withdrawn from the circulation in a sterile 
way without clotting, to bathe one side of a semipermeable, across which 
counter flows from prepared dialysate and then be returned safely to the 
patient. Cannulae, anticoagulation, sterility, air embolism-all of these were 
major mattering in the early days-now solved by technologic advances. 
Initially all dialysis was seen as a “bridge“to renal recovery from injury, or 
until renal transplantation could take place. 
Peritoneal dialysis (e.g. CAPD) has had s shorter history (starting 1975) as a 
chronic RRT. There were, as for HD, many technical problems in initial use. 
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Long-term technique survival is rarer for CAPD than for HD. In civilized 
society, patients should be encouraged to exercise choice about how they 
dialyse; this helps to involve the patient in his own long term-care. Many 
patients do not have the physical or mental attributes to permit self-dialysis; in 
these cases, unit-based HD is preferred. 
2.3.3.2 Hemodialysis 
Modern HD can take place at home, in a dialysis centre (satellite dialysis unit) 
or a main hospital site. Blood access is best achieved using an arteriovenous 
fistula; these depend on arterialization of peripheral veins in upper or lower 
arm due to exposure of veins to arterial pressure. This process can take 4 -
 8 weeks to occur insertion. Vessel wall become thicker. Short and long-term 
tunneled venous catheters, single- or double-lumen, are further alternatives. 
Anticoagulation is achieved typically with a bolus and then an infusion of 
intravenous heparin. Treatment duration is typically for 4 hours, thrice-weekly 
with arterial blood flow of 250-300 ml/min and dialysate flow of 500 -
 600 ml/min. The dialysis solution is essential a mixture of electrolytes in water 
with a composition approximating to extracellular fluid into which solute 
diffuse. The ionic concentration of the dialysis fluid can be manipulated to 
control rate and extend of electrolyte transfer. Calcium and bicarbonate 
concentration can also be increased in dialysis fluid to promote diffusion into 
blood as replacement therapy. By manipulating the hydrostatic pressure of the 
dialysate and blood circuits, extend and rate of water removal by ultrafiltration 
can be controlled. 
Hemodynamic complications arise from the circulatory response mediated by 
receptors and the autonomic and sympathetic system. Hypotension occurs in 
10-30% of dialysis treatment. The etiopathogenesis is complex and multifacto-
rial –including neuropathy, antihypertensive medication, sepsis, increased body 
core temperature, hypoalbuminemia, and anemia. Increase sympathetic drive, 
accumulation of pressor compounds, and erythropoietin are other reasons for 
dialysis patients to be hypertensive. Long, slow dialysis, or more recently, 
daily dialysis, can normalize blood pressure without use of antihypertensives. 
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Sudden death rates are vastly increased in dialysis patients. This is especially 
the case for type 1 diabetics on HD. 80% of these sudden deaths are as a result 
of ventricular fibrillation. End-of-dialysis hypokalemia, hypocalcemia, and 
hypomagnesemia, and mild intradialytic hypoxemia are partly to blame, as are 
malignant ventricular re-entrant arrythmias resulting from coronary artery 
disease. 
Arteriovenous fistulae are robust and by far the most reliable form of dialysis 
access. Stenosis at the site of arteriovenous anastomosis can occur early, and 
prevent maturation. Thanks to local aneurismal dilatation, increasing venous 
pressure, and reduce dialysis solute clearances. Angioplasty can resolve these 
difficulties. ACE inhibition may reduce the tendency to fistula stenosis; poor 
calcium-phosphate control may contribute to it. A good fistula can provide 
excellent dialysis for two decades. Central venous lines are a poor (but for 
patients necessary) substitute for a fistula. Infection and trombosis are chief 
complications. 
2.3.3.3 Peritoneal dialysis 
The peritoneal membrane is semi-permeable and therefore permits dialysis if 
a sterile dialysate is placed into the abdominal cavity. Transport across the 
peritoneal membrane is linked to vascular surface area and to intrinsic peri-
toneal permeability. 
There are many different designs of peritoneal catheter now available. Usually 
one or two cuffs provoke subcutaneous fibrosis (help to stay the catheter). 
Peritoneal dialysis (PD) involves filling the abdominal cavity with dialysis 
fluid, allowing this fluid to live on for a while, and then draining it out to be 
replaced with a fresh dialysate. This takes place (as CAPD) typically using 2-
2,5 liter volumes, four to five times daily, 7 days a week. All PD fluids contain 
sodium, calcium, magnesium, and chloride. Lactate is usually buffered. The 
osmotic agent is glucose-all PD is grossly hyperosmolar, and, at pH 5,2 hardly 
physiological. 
Without doubt the most important complication of PD is infection in the peri-
toneal cavity. Infection can be virtually asymptomatic or cause severe systemic 
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upset. Symptoms are usually colicky abdominal pain and cloudy effluent (con-
tent white blood cells). Fever and raised CRP are typical. Empirical antibiotics 
are started (as either intravenous or intraperitoneal boluses, then added to the 
bags) and then changed as appropriate once PD fluid cultures have been 
analysed. 
2.4 Antibiotics used in nephrology 
The basic goal of antibiotic therapy is to achieve a steady state blood and tissue 
level that is both effective and non-toxic. To adjust maintenance therapy for 





 have suggested the following approach with requires knowledge 
concerning the relationship between the overall rate constant for elimination of 
the drug from the body as a percent per hour (K%) and the creatinine clearance 
(CrCl).
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 Antibiotics used in nephrology could be divided into classes are 
similar to classes used in other areas of medical and surgical therapy. Choice of 
representatives in particular group is reflected mainly by pharmacokinetic and 
pharmacodynamic features that are relevant to nephrological patient, especially 
such as possibility for: 
1. decreased oral absorption 
2. increased volume of distribution 
3. decreased elimination 
4. empirical judgement about infectious agents 
5. increased potential for nephrotoxicity 
2.4.1 Division of Antibiotics 
Antibiotics are drugs derived wholly or partially from certain microorganisms 
and are used to treat bacterial or fungal infections. They are ineffective against 
viruses. Antibiotics either kill microorganisms or stop them from reproducing, 
allowing the body's natural defences to eliminate them. Each antibiotic is 
effective only against certain bacteria. In selecting an antibiotic to treat an 
infection is need to recognise to which bacterium is responsible. If there is one 
antibiotic that is predictably effective against all of these bacteria, further 
testing is not needed. For infections that may be caused by many different 
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types of bacteria or by bacteria whose susceptibility to antibiotics is not 
predictable, a laboratory will be asked to identify the infecting bacterium from 
samples of blood, urine, or tissue taken from the. The infecting bacterium is 
then tested for susceptibility to a variety of antibiotics. Antibiotics that are 
effective in the laboratory do not necessarily work in an infected person, 
however. The effectiveness of the treatment depends on how well the drug is 
absorbed into the bloodstream, how much of the drug reaches the sites of 
infection in the body, and how quickly the body eliminates the drug. In 
selecting which antibiotic to use should be also considers the nature and 
seriousness of the infection, the drug's possible side effects, the possibility of 
allergies or other serious reactions to the drug, and the cost of the drug. Combi-
nations of antibiotics are sometimes needed to treat severe infections, 
particularly in the first days when the bacterium's sensitivity to antibiotics is 
not known. Combinations are also important for certain infections in which the 
bacterium rapidly develops resistance to a single antibiotic. Infections caused 
by more than one bacterium, in which each bacterium is susceptible to 
a different antibiotic, are also treated with a combination of antibiotics. 
Division may be into bacteriostatically or bactericidally acting antibiotics. The 
other stand-point is subsumption of antibiotics into the groups according 
pharmacotherapeutical effect. Among activity mechanism belongs impair 
synthesis of bacterial wall from peptidoglycan, inhibition of protein synthesis, 
inhibition of nucleic acid synthesis or damage of the function of cytoplasmatic 
membrane. 
2.4.1.1 Antibiotic classes 
Penicillins 
These are mainly bactericidal agents that impair synthesis of the bacterial cell 
wall. The penicillins may be classified into subgroups on the basis of their 
structure, β-lactamase susceptibility, and spectrum of action. Dosages of these 
agents vary according to the type and severity of infection. They are generally 
well tolerated. Hypersensitivity and GI reaction are the most common side 
effects, granulocytopenia, hemolytic anemia, bleeding intestinal nephritis, 
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hepatitis may occur. Patients allergic to one of penicillin compound are likely 
to be allergic to other such compound. Division of penicillins may be into 4 
groups or subsequent; 
1. Basic: Penicillin G, Penicillin V 
2. Broader-spectrum: Ampicillin, Amoxicillin, and Ticarcillin 
3. Penicillinase resistant: Oxacillin 
4. Combination with penicillinase inhibitors: Amoxiclav, Sultamicillin 
Cephalosporins 
The cephalosporins are mainly bactericidal, rapidly and constantly expanding 
group of β-lactam antibiotics. They are bactericidal and inhibit bacterial cell 
wall like penicillins. The adverse effect of this group are mainly 
hypersensitivity reaction, local pain (with intramuscular use), and 
trombophlebitis (with intravenous use). Primarily the kidney excretes most 
cephalosporins; dosages must be reduced in the presents of renal failure. 
Cephalosporins can be divided into 4 generation groups. Agents: Cefalexin, 
Cefuroxime, Ceftazidime, Cefepime. 
Aminoglycosides 
The aminoglycosides are mainly bactericidal drugs that act by binding 
irreversibly to the ribosomal subunit of susceptible bacteria. They are not 
absorbed from the GI tract and must be administered intravenously or 
intramuscularly. These agents are ineffective against anaerobes and 
enterococci, so they are used chiefly to treat infection caused by aerobic gram-
negative bacilli. 
Blood level should be monitored to ensure proper dosing; peak levels may be 
lower than expected in patients with an expanded extracellular volume. The 
major toxicities include renal damage and ototoxicity (vestibular or 
auditory).The aminoglycosides are extremely active antibiotics that have 
proved to be clinically effective against many serious infections, and these 
agents have become inexpensive. New tendency to improve the toxic-to-the-
rapy ratio of aminoglycosides include on-daily dosage schedule. To determine 
the future role of them, the cost-effectiveness needs to be compared directly 
with that of the new β-lactams and the fluoroquinolones. 
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Agents: Gentamicin, Tobramycin, Amikacin. 
Tetracyclines 
Tetracyclines are mainly bacteriostatic drugs that were originally employed 
because of their broad spectrum of activity against both gram-positive and 
gram-negative bacteria. The emergence of resistance among gram-negative 
bacilli, group A streptococci, and pneumococci and the frequency of 
superinfections have also tended to decrease indication for their use. They are 
useful in the treatment of pneumonia (caused by Mycoplasma pneumoniae), 
urogenital infection (C. trichomatis), and other chlamydial diseases. The 
tetracyclines are available in oral and intravenous formulation, its long half-
time allows administration in one or two daily doses, and it does not 
accumulate in the presence of renal failure. These should be not given to 
children younger than 9 years or to pregnant woman, because of permanent 
discoloration of teeth may result. Other potential side effects include photo-
toxicity, allergic reactions, and enterocolitis. Main agent: Doxycycline. 
Macrolides 
The macrolides are mainly bacteriostatic drugs, composed of 14, 15, or 16 
carbon atom joined together in a complex, central, circular molecule that is 
linked to various side chains. Mainly used agents: Erythromycin, Clarithro-
mycin, Azithromycin. 
Erythromycin is excreted a large extent in the bile and only to minor degree in 
the urine. The dosage need not to be altered in presence of renal insufficiency 
It is active against gram-positive bacteria such as penicillin-sensitive 
S.pneumoniae, further Mycoplasma, Legionella, and Chlamydia species, it is 
an effective treatment for patient with atypical pneumonia. 
Clarithromycin exhibit excellence activity against M. catarrhalis and H. influ-
enza, which therefore makes it an attractive agent for the treatment of 
respiratory tract infection. The drug is being used for monotherapy for Helico-
bacter pylori gastric infection. 
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Trimetoprim-sulfamethoxazole 
Used of this combination (mainly bactericidal) extended the list of clinical 
situations in which sulfonamides appear to be of value; recurrent bacteriuria 
and urinary tract infection, prostatitis. 
Fluoroquinolones 
The fluoroquinolones are bactericidal compounds that act by inhibiting DNA 
gyrase with broad-spectrum activity. Most enteric gram-negative bacilli are 
highly susceptible; common GI pathogens, such as Salmonella, Shigella, and 
Campylobacter species, are very sensitive. They are rapidly absorbed from the 
GI tract. Penetration into body fluids and tissues is generally excellent; thera-
peutic concentration are readily achieve in blister fluid, bile, urine, saliva and 
sputum, bone, muscle and prostate. Most of them are eliminated by glomerular 
filtration and tubular secretion, and their dosage should be reduced in the pre-
sence of moderately severe renal failure. The fluoroquinolones appear to be 
very well tolerated, with mild GI and CNS side effects, or rash. They have 
been useful clinically in a variety of infections, including urinary tract, genital, 
prostate, GI, respiratory tract, soft tissue, and bone infection. Because of their 
extraordinary broad antimicrobial activity, their favorable pharmacokinetics, 
and their low toxicity, the fluoroquinolones are extremely valuable new drugs. 
Nitrofurantoin 
Nitrofurantoin is readily absorbed from the GI tract and rapidly excreted. Anti-
bacterial level is achieved in the urinary tract. That is why; this drug should be 
employed only in the treatment of uncomplicated mild urinary tract infection or 
for its prevention. The spectrum of antibacterial activity includes E. coli, 
enterococci, and some strains of Klebsiella and Enterobacter. It should be not 
administered when there is significant impairment of renal function.7 
2.4.2 Peculiarities of pharmacokinetic/dynamic in nephrology 
patients 
Knowledge of pharmacokinetic principles is essential to understand dosage 
modification for drugs used in patients in renal failure. Dosage modification is 
indicated either where drugs have a low therapeutic index, or where renal 
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mechanisms play a major role in drug elimination. Drug renal clearance can be 
indexed to creatinine clearance in order to measure the degree of drug 
elimination impairment. In addition to effects on drug elimination, renal failure 
may also alter drug absorption, distribution, protein binding, and metabolism. 
Dialysis regimens, by eliminating drugs to a greater or lesser degree, have 
implications for drug therapy.
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Further are mentioned select antibiotics, which were used for treatment of 
dialysed patients in KMUK. Providing that GFR of patients with CRF less than 
10 ml/min. 
Penicillin 
Dosage adjustment may be necessary in patients with impaired liver function 
when they also have renal failure. In this situation the liver may be a major 
excretion route. Excretion is considerably prolonged in patients with renal 
function impairment, there out by kidney 20-40%. 
Cefuroxime 
Injection: the following dosage reduction is recommended 5% to 10% of the 
usual dose in patients with severe renal failure. It means 750mg every 24 
hours. 
Oral: recommendations were provided based on a usual standard dose defined 
as 250 to 500 milligrams orally every 8 hours, then adjustment dosage is every 
48 hours. 
Ceftazidime 
An adjustment is recommended 500mg every 48 hours. 
Oxacillin 
Dosage adjustment of oxacillin is not required in patients with renal failure. 
Amoxicillin 
Generally, dose reduction is not required unless severe renal impairment. Then 
is 250 mg or 500 mg every 24 hours. Additional doses should be administered 
both during and at the end of dialysis. 
Amikacin, gentamicin 
Adjustment may be based on serum level measurements, e.g., recommended 
therapeutic amikacin serum levels are: peak levels of approximately 25 
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micrograms/milliliter and trough levels of approximately 5 to 8 
micrograms/milliliter). Adjustments may be 20% to 30% of the dose every 24 
to 48 hours. 
Vancomycin 
Administration should be 500 mg every 48 to 96 hours. If the patient is anuric, 
a dose of 1000 milligrams every 7 to 10 days has been recommended. The 
initial dosage should not be less than 15 mg/kg. The optimal dose and interval 
can be determined based on serum drug concentrations. 
Ampicillin 
Patients should receive common dosage of ampicillin every 12 to 16 hours. 
Ciprofloxacin 
Intravenous or oral ciprofloxacin may be used in dosage 200 to 400 milligrams 
given every 18 to 24 hours. 
Clarithromycin 
In the presence of severe renal impairment the dose should be halved or the 
dosing interval doubled. 
Doxycycline 
Dosage adjustments are not required. The usual recommended dose will not 
lead to accumulation of doxycycline in the serum. 
Nitrofurantoin, trimetoprim 




2.5 Pharmacotherapeutical problems as a reason for 
non rationality 
The goal of pharmaceutical care is to prevent drug therapy problems before 
they occur and to resolve problems that already exist. It concern to promote 
health, prevent disease, and assure that drug therapy regiments are safe and 
effective. A drug therapy problem, however, is a patient problem that is either 
caused by or may be treated with a drug.
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 However, despite improved avail-
ability, pharmaceuticals are frequently used irrationally. The International Net-
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There are no “magic bullets” for improving the quality of health care. There 
are, however, a wide range of interventions available that, if used appropria-




2.5.1 General considerations 
What is drug therapy problem? These are undesirable events or risks 
experienced by the patient that are involve or are suspected to involve drug 
therapy and inhibit or delay him/her problem achieving the desired goals of 
therapy. Drug therapy problems are identified during assessment process, so 
that they can be resolved through individualized changes in patient’s drug 
therapy regimens. Recognize these troubles may be by sociological and 
pharmacological knowledge of the patient, disease, and drug therapy 
information collected during the assessment step. 
How to discover pharmacotherapeutical problems? Practitioners gather history, 
evaluate data, and identify drug therapy problems; they must also determine the 
cause of each problem. The cause is important because it suggest potential 
therapeutic plans that may be implemented to solve the problem. A pharma-
ceutical care approach to practice is required to be able to identify a patient 
with a problem, rather than a problem with a prescription. 
Drug therapy problems may be actual or potential. The distinction between the 
two is important, but is not always immediately apparent in practice. An actual 
problem is one that has already occurred, and thus the practitioners must try to 
fix it. A potential problem is one that is likely occurring. When an actual drug 
problem exist, then is necessary to resolve it, beside a potential problem is 
needful to prevent it.
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Short-course antibiotic therapy should be reason for out-patients, where 
compliance has always been problem. Investigators attempt to formalize the 




2.5.2 Special considerations in pharmaceutical care 
To identify, resolve, and prevent drug therapy problems, the practitioner must 
understand how patients with drug therapy present in the clinical settings.  
Categories of drug therapy problems and common causes: unnecessary drug 
therapy, need for additional drug therapy, ineffective drug, dosage too low or 
too high, adverse drug reaction, non-compliance. 
Once categorized, it is then necessary to identify the cause for each drug 
therapy problem. When knowing the cause of problem, it leads to the best 
solution for the patient. The problems have to be prioritized to determine which 
should be addressed first and where should be targeted the biggest pharma-
ceutical care and appropriate interventions.
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2.5.2.1  Specificities in nephrology department 
Type of patients and infections treated in nephrology department is quite 
mosaic and reflects broad variety of infections with all possible pharmaco-
kinetic and pharmacodynamic factors influencing antibioticotherapy. Problems 
relevant to nephrological department is not known and should be investigated 
in detail. 
To find specific problems in nephrology department there are few steps have to 
be discovered and resolved. Firstly is necessary to describe the situation in 
chosen area, what we proceed with data collection of dialysed patients. Next 
step is evaluation of these inputs. 
We tried to evaluate adherence to peer reviewed recommendations, so that we 
divided the drug using into three segments according the approaching the 
rational use of drugs. In more details, these segments are described further. 
Final goal of this work was to help physicians from nephrology department to 
re-evaluate their prescribing behaviours and improve these behaviours in 
future, if possible. 
As one of drug problems we found the deviation from choice of the suitable 
medications for relevant infection disease. These were indications not fitting 
under the first or alternative choice for specific illnesses. Often, it is used 
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antibiotic with a wide broad spectrum of effectiveness, which leads to spread 
resistance. 
Next distinguished problem is highly modest of use the microbial test for 
discover micro-organisms, which are responsible for emerging the infection. 
Even we disclose some situation, when the culture test was proceed and 
identify the sensitivity and resistance, but finally was prescribed the 
antimicrobial agent with resistance for respective bacteria regimen.  
After presentation and discussion with physicians about possible problems, 
suitable steps and intervention for improvement the pharmaceutical care can be 
provided. 
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3 PRACTICAL PART 
3.1 Background and Objectives 
Theoretical evaluation of situation and possibilities of antibioticotherapy in 
dialysis population revealed lack of knowledge of pharmaceutical care in this 
area. 
Since, one of first steps in pharmaceutical care is the evaluation of the situation 
to be intervened, we realised the need for filling this gap. We have chosen one 
nephrological department that is representative for tertiary care in EU country. 
Since this was first type of study in this setting, retrospective study design was 
chosen.  
Research protocol was initiated to gather this information. Ethical committee 
approval before start of study was obtained. 
Aim 
The primary aim of this study was to investigate non-adherences to national 
guidelines on rational antibioticotherapy as a one of main aspects in rationality 
of antibioticotherapy in patients treated with dialysis.  
Tasks 
To reach this aim we had to solve several related tasks: 
1. Describe ABT cases in patients treated with dialysis treatment modality 
during two consecutive years; 
2. Investigate level of non-adherence of the prescribed antimicrobial drugs to 
nationally available guidelines; 
3. Investigate reasons for non-adherence as this is perceived by prescribing 
physicians; 
4. Compare the number of antibiotic prescriptions and incidents of non-
adherences observed in case of dialysis population with out-patients treated in 
general practice during one year. 
3.2 Setting and study design 
Our main set included dialysed patients in Clinics of Kaunas Medical Univer-
sity (KMUK) in Lithuania. Group I contains patients who are registered in 
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nephrology department in KMUK with diagnosis renal replacement therapy in 
2006, at that time of investigation (September 2006–January 2007) and were 
treated during period of 2005 and 2006, Group II contained historical data 
gathered for year 2005 in one Family practice clinic that stayed in KMUK in 
January 2006. 
These patients needed special attitude concerning their treatment. We checked 
the choices of particularly agents and evaluated, if it was suitable for the 
rational use of drug policy, as this is recommended by national guidelines on 
rational antibioticotherapy. 
After evaluating antibioticotherapy cases and considering certain cases of non-
adherence, we studied which factors are the most influential in guiding non-
adherent antimicrobial choices. Main focus was to investigate the level of non-
adherence as the one of the main aspects of rationality in antibioticotherapy.  
In general we evaluated the data from two different settings. First group (I gr.) 
included dialysed patients (DP) and second group (II gr.) consisted from 
patients, who were from general practice (GP). 
The main quest was to discover how physicians respect and follow the national 
guidelines. Our effort was aimed at evaluation of cases of non-adherence to 
note for guidelines on rational prescribing of antibiotics (Maciulaitis et al., 
2004)
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. Effort was to gain the areas for future pharmaceutical care inter-
ventions. 
Towards comparison we distribute our cohort according years namely 2005 
and 2006. Assembled information concerned several units of therapy: treatment 
and prophylaxis (medical or surgical).  
 Treatment - that means kind of chosen antibiotic with dose, dosage, 
duration of treatment, and way of administration of the drugs. Term 
therapy case correspond a fact, that for one indication of infection 
disease, patient was treated with individual kind of antibiotic. There are 
some cases, when was necessary to use combined antibiotic therapy, 
and then each case is described separately. Non-adherence was assessed 
as per relevance for indication, efficacy, and safety. 
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 Indication for treatment: shows, if culture of sensitivity of infective 
organism was made or patient was treated empirically. 
 Efficacy: deals with objective data (renal clearance, CRP, neutrophils, 
WBC etc.)-if available. 
 Safety: mentions subjective data during or after treatment (if available), 
monitoring of drugs, which has like a side effect damage of kidney. 
Prophylaxis - that means kind of chosen antibiotic with dose, dosage, duration 
of prophylaxis, and way of administration of the drugs.  
Our interpretation of aspects of rational prescriptions of antibiotics arises from 
national Lithuanian guideline
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. Primarily we obtained all of approachable data 
from a well-arranged table. For majority of ABT cases there is available 
information regarding etiology of infection, type of prescribed antibiotics, 
dose, dosage, duration, other information concerning specific details like a 
CRB, WBC, leucocytes, cultural test, etc. According to the guideline we 
assigned to every cases appropriate predicted drug suitable for particular 
infection. Diagnosis was carried out either empirically or on the based of 
microbiological examination. With a cooperation of doctor’s team we 
evaluated three possibilities namely an adherence, reasonable, and non-
adherence. 
Term adherence involves rational advancement according appropriate guide-
lines and rules. 
Term reasonable in this document means that some details differ from 
guideline, especially in dialysed patients with concomitant diseases the doctor 
have to assess circumstances concerning separately patient eventually case. 
Reasonable cases could be further developed for optimization of guideline.  
Term non-adherence included every items, where evaluation of case 
considerably deviate from accurate practice. For example when the doctor has 
sufficient amount of information about etiological agent and sensitivity and 
resistance tests and decide for that kind of antibiotic, which the test place 
among the resistant. Use unnecessarily wide spectrum of antibiotics for not 
significant disease, treatment with such a kind of antibiotic, which for dialysed 
patients is better to obviate. 
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First of all we confront the outcomes between year 2005 and 2006 in term of 
rational advancement. Followed information convey of quantification and 
comparison in our set. Our results arise from entire accessible information 
evaluated one by one patient.  
We compared the data obtained in year 2005 with data from 2006 for DP and 
for the same year 2005 for GP population.  
Data for patients in I group were collected from the medical charts from 
Department of nephrology. All acquired information was recorded into the 
paper form (see Appendix 1). Data were gained with compliant cooperation of 
pharmaceutical students from fourth class and doctors from nephrology 
department. Comparative set of patients from II group were presented in study 
of Petrikaité at al., 2006 article
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 and were retrospectively collected from 
Department of Family practice, Kaunas University of Medicine. This study 
records regarding the prescription of antibiotics during period 1
st
 of January to 
31
st
 of December 2005. The main goal was to evaluate the use of antibiotics in 
daily family doctor’s practice and non-adherence to guidelines on rational 
antibiotic therapy. 
The outcome variables were: 
1. The based information about patient (11 items) 
2. Pharmacotherapy (kind of antibiotic, the dosage with duration of 
antibiotic treatment, distinguish oral and intravenous administration, 
aim of treatment, indication for treatment 
3. Infection disease (description with its markers) 
4. Evaluation (reason why antibiotics are prescribed not rationally) 
5. Table (survey of treatment) 
As a design, we used retrospective analysis and comparison of all available 
antibioticotherapy cases in DP during years 2005 and 2006. Comparative data 
were collected with GP for year 2005. 
Statistical analysis Data were processed with SPSS 16,0 using descriptive and 
comparative statistics for nonparametric values (Mann-Whitney test). 
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Proband requirements 
Into the study were included patients, who attended the dialysis unit (start at 
least from year 2005) and were treated in nephrology department. 
For simplification further we mentioned them like a dialysed patients DP and 




3.3 Main outcome measures 
Demographic data of patients received antibiotics prescriptions.
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 We accom-
plished quantification of non-adherence to national guideline and comparison 
results between years 2005 and 2006 and outcomes from two different 
therapeutic settings (DP and GP) during year 2005. Perceived reasons of non-
adherence to guideline is a necessity for definition of major area for 
improvement outcomes in pharmaceutical care in this Clinic. 
3.4 Results 
3.4.1 Description set 
Our set of the group I attended dialysis unit three times per a week according 
individual schedule. Doctors in this department hold an appointment as general 
practitioner also (approximately in 99% of cases), it means these physicians are 
responsible for drug prescribing and all implications arise from that fact. 
Overall, we gained information from 113 DP patients. Twelve physicians 
provide health care for these patients. Number of treated patients (DP who 
received antimicrobial agent prescription) were 40 (year 2005) and 49 (year 
2006). In total, there were 197 cases of therapy; from that 88 cases in year 
2005 and 109 cases in year 2006. Total number of treated patients was 72; 
patients, who were not treated during 2005 and 2006 is 41. It means that some 
of these patients were sick in both years 2005 and year 2006. 
Group II contains 1285 patients; number of therapy cases 71, and number of 
treated patients was 42. 
For the simplification reason we describe in more detail further just group I 
(group of main importance) and the group II we leave for final comparison of 
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non-adherence to guidelines on rational antibiotic therapy; it is introduced and 
describe subsequently. 
Description data about the set are shown in table 1. 









































Table 1: Settings of patients from both comparing groups-general informations 
in patient’s numbers (and %). 
In summary, it seems that I group patients had higher prevalence of morbidity 
(35,5 and 43,3% annually) than II group patients (3,3% annually). Majority of 
patients (63,7%) were treated with antibiotics during 2 years. 
3.4.2 Baseline characteristics 
As a baseline data we observed besides demographic characteristics (age and 
gender) also additional considerable items - weight, concomitant diseases (the 
most frequent type), and number of antibiotic treatment items per patient. 
Results of frequency analysis concerning with answers for previous questions 
are draw up in tables 2 to 5 and Graph 1. 
In our set of 113 patients there were 57,5% male and 42,5% female, their 
average age is 58,9 year. The prevalence in male cases are higher may be due 
to the risk factors shares by cardiovascular disease and prostatic difficulties.
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And number of ABT items per patient was 1,3 involve both two years. 
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No of patients 
(n=100%) 




113 57.5 42.5 58.9(15,58) 1.3 
Table 2: Baseline data about dialysed patients for both years 2005 and 2006 (in 
patient’s numbers and %). 
 




































Graph 1: Age-category distribution of DP set (in patient’s %). 
 
In summary, gender distribution is approximately equal; the average data 
about age structure in monitored file is evident from the table 2. The most 
patients are in age 51-60 (21,2%), 61-70 (29,2%) and 71-80 (22,1%) years. Just 
6,2% of our sample composes patients till 30 years. The ages in this group 
varied from 20 to 84 years old. 
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Regarding to concomitant diseases, all DP suffer with several relevance from 
hypertension and anemia, what is result from damage of kidney. The noc-
sequent concomitant diseases are from the highest representation hyperpara-
thyroidism (HPTD)-15,9% follows with diabetes mellitus I, II (D I, II) and 
cardiomyopathia (CMP) both with 15,0%, chronic glomerulonephritis (GNCH) 
12,4%, chronic pyelonephritis (PCH) 8,0%, and hyperplasia prostate 12,4% (in 
this case we ratiocinate 100%=65 males). The most patients of the study 38,9% 
are without consequential concomitant diseases. 
 
Concomitant disease Total (113=100%) Males (65=100%) 
HPTD 15.9  
D I, II 15.0  
CMP 15.0  
GNCH 12.4  
PCH 8.0  
HP  12.3 
Without conc. disease 38.9  
Table 4: Survey of concomitant disease (in patient’s%). 
 
In summary, table 5 draw up above mentioned characteristics of our patient’s 
set and offer general survey about monitored group. Mean age of dialysed 
patients is 58,9 years. Difference between genders is not prominent. Mostly of 




Number of patients 113 
Mean age(±SD) 58,9 (±15,58) 
Gender 57,5% male 
42,5% female 
Item of ABT per patient 1,3 

















The most frequent concomitant diseases:  
HPTD 












Table 5: Summary of results from the based characteristic of patient’s set (in 
patient’s %). 
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3.4.3 Pharmacotherapy and prophylaxis 
In our survey extensive part deals with ABT. In our set of whole 113 patients 
we observed patients who are covered up therapy with antibiotics. Observed 
patients received the most of all amoxicillin 14,7% in year 2005, respectively 
27,5% in year 2006, follows by cefuroxime 15,6% (2005), 20,2% (2006). 
Other prescribed antibiotics are summarized in followed table 6. Pharma-





2005 (88=100%) 2006 (109=100%) 2005&2006 
(197=100%) 
Amoxicillin 14.7 27.5 23,4 
Cefuroxime 15.6 20.2 19,8 
Ciprofloxacin 11.9 11.0 12,7 
Penicillin 7.3 0.9 4,6 
Vancomycin 1.8 9.2 6.1 
Oxacillin 3.7 5.5 5.1 
Biseptol 5.5 1.8 4.1 
Clarithromycin 3.7 3.7 4.1 
Ceftazidime 0.9 5.5 3.6 
Cefazolin 3,7 3,7 4,1 
Gentamicin 2,8 0,9 2,0 
Amikacin 2,8 0,0 1,5 
Ampicillin 0,9 1,8 1,5 
Doxycycline 0,9 2,8 2,0 
Trimetoprim 0,0 1,8 1,0 
Other

 18.3 14.7 18.3 
Table 6: Administered antibiotics in observed files (in antibiotics %). 
 
                                                 

Others: Ampicillin/sulbactam,, Ceftriaxon,, Ofloxacini, Piperacillin/tazobactam 
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Graph 2: Selection of administered antibiotics in observed files during both 
years 2005 and 2006 (in patient’s %). 
 
From data fields we find that the duration of the patient’s treatment take the 
most of all 6-10 days. Further are patients, who are treated 5 or less days. This 
interval is convenient for patient, who not well cooperate with a doctor and is 
suitable for their indication of infection. Also there is quite large number of 
cases, where we can’t obtained this information namely proximately a third of 




2005 (88=100%) 2006(109=100%) 2005&2006 
(297=100%) 
≤5 17,0 16,5 16,8 
6-10 22,7 33,0 28,4 
11-15 10,2 9,2 9,6 
16-20 3,4 3,7 3,6 
≥21 1,1 4,6 3,0 
Invaluable 45,5 33,0 38,6 
Table: 7: Therapy duration (in patient’s %). 
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Main part of administered drugs was given by intravenous way, but there is a 
weak amount of information to disclose in percentage share. Also in many 
cases the intravenous way of drug delivery was switch into the oral way, when 
relevance of infection has diminished.  
In summary, from (frequency analysis) results of pharmacotherapy and 
prophylaxis emerged consequent actualities: 
 
23,4% of patients were treated with Amoxicillin, 19,8% - with cefuroxime, 
and 12,7% – with ciprofloxacin 
Most often (in 28,4% of patients) duration of treatment takes 6-10 days 
3.4.4 Indication of infection diseases 
Spectrum of infection diseases in our files of patients is relatively extensive 
and is displayed in table 8 and in graph 3. 
 
Kind of infection 2005 (88=100%) 2006 (109=100%) 2005&2006 
(197=100%) 
RTI 35,2 37,6 36,5 




17,0 22,9 20,3 
GIT 8,0 7,3 7,6 




4,5 0,0 2,0 
Other 5,7 2,8 4,1 
Table: 8: Distribution of infection diseases in patients set (in patient’s %). 
 
In summary, despite of that fact it is evident that some of them appear 
more frequently. These are respiratory tract infections (RTI), especially 
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pneumonia that represent more then third of all cases, followed by urinary 
tract infections (UTI), which gain approximately quarter of infections, 
dermatogenic infection with 20,3% (here is included also infections related 
with inserted catheter), infections covering gastrointestinal tract (GIT) 
takes 7,6 %, otorhinolaryngology (ORL) infections have 4,1%, infections 
after kidney transplantation takes 2,0%, and the other rare occur belongs 
4,1% from spectrum of infections. Formerly mentioned illnesses often 
merge into the chronic form. Because of serious variation of infections 
some patients must be hospitalized during treatment. There are not 
significant differences between year 2005 and 2006. 
 
 Pneumonia UTI 
2005(88=100%)  26,1 23,9 
2006(109=100%)  28,4 26,6 
2005&2006 (197=100%)  27,4 25,4 
Table: 9: Representation pneumonia and UTI like the most frequent illness in 
spectrum of infection diseases (in patient’s %). 
 

























































Graph 3: Distribution of infection diseases of all cases in both years 2005 and 
2006 (in patient’s %). 
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As mentioned above, pneumonia itself like an infection disease covers 27,4% 
of all therapy cases and get into the most frequent disease of our set. The 
biggest representation of antibiotics, which are used to treat pneumonia, was 
cefuroxime with 37,0% and amoxicillin with 31,5% of cases. Nevertheless 
drug of the first choice is penicillin, which was used only in 16,7% cases of 
treatment. 
Concerning UTI, this illnesses were treated mostly with ciprofloxacin, namely 
in case of 30% of UTI, followed by cefuroxime with 20%. These do not belong 
to the drug of the first choice (possibly as alternatives). The agent of first 
choice should be trimethoprim, which in this situation was utilized just in 4% 
of cases. Another significant fact was prescription of trimethoprim with 
sulfamethoxazol (Biseptol), in 14% of cases, while this agent is not re-
commended to patients with RRT. Summary outlook is in table 10. 
 
Pneumonia 
 Total (54=100%) No % 
Cefuroxime 20 37,0 
Amoxicillin 17 31,5 
Penicillin 9 16,7 
UTI 
 Total (50=100%) No % 
Ciprofloxacin 15 30,0 
Cefuroxime 10 20,0 
Biseptol 7 14,0 
Trimetoprim 2 4,0 
Table 10: Apply relevant kind of antibiotics for two the most frequent illness, 
usage of the most prescribed antibiotics for both years 2005 and 2006 (in 
antibiotic’s numbers and %). 
 




37,0% of patient with pneumonia were treated with cefuroxime 
31,5% of patient with pneumonia were treated with amoxicillin 
Just 16,7 % of patient with pneumonia were treated with penicillin 
 
30% of patient with UTI were treated with ciprofloxacin 
20% of patient with UTI were treated with cefuroxime 
Just 4% patient with UTI were treated with trimetoprim 
3.4.5 Indication of treatment 
According to good pharmaceutical care, before the initiation of patient’s treat-
ment should be carried out the bacteriologic test and ascertainment sensitivity 
and resistance for appropriate antibiotics. However most of treatment in this 
department is provided empirically.  Bacteriological tests were performed in 
less then third of cases. We can see appreciable improvement in year 2006 with 
contrast to previous year 2005. These information displays graph 4 and 5. 
 
Performance of culture test 2005
ATBgram 20.5% No test 79.5%
 
Performance of culture test 2006
ATBgram 26.6% No test 73.4%
 
Graph 4: Performance of cultural test 
in year 2005 (in patient’s %). 
Graph 5: Performance of cultural test 
in year 2006 (in patient’s %). 
3.4.6 Rationality of ABT in DP set between year 2005 and 
2006 
From all cases of ABT there were 88 patients in 2005 and 109 in 2006 from 
that non-adherence was considered in 14 cases for year 2005 and 19 in 
2006. This is statistically nonsignificant (p=0,3, Mann Whitney test). More 
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Reasonable 47,7 45,0 46,2 
Adherence 36,4 37,6 37,1 
Non-adherence 15,9 17,4 16,8 
Table 11: Evaluation of rationality aspects in prescription of antibiotics (in 
patient’s %). 
 













Graph 6: Evaluation of adherence to national recommendation in years 2005 
and 2006 (in patient’s %). 
 
The situation on this department we can designate like a favourable from the 
viewpoint access to rational drug use. In the year 2006 appear mild impro-
vement, the non-adherence to guidelines decrease from 18,2% to 13,8%. 
From the considered drug therapy problems the biggest part belongs to 
indication for choice of proper kind of antibiotics to the particular disease. It 
seems that usual preference is given to that one, which has greater spectrum to 
cover larger amount of bacteria. Another reason for apparent failure of 
antimicrobial therapy is when a viral illness (e.g. upper and lower respiratory 
tract infection) is treated with antibacterial agents. Further often problem is 
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dosage too high, than is sufficient. Especially for DP this presents an issue. 
Some cases are unclear, in our case it means, that we have not enough 


















Graph 7: Structure of drug therapy problems in DP in years 2005 and 2006 (in 
patient’s %). 
 
In summary, main problems raise in choice of indications. Same pattern is 
relevant for both years in DP population. 
3.4.7 Comparison of two different patients settings in rational 
drug use according recommendations 
Additional comparison from two different patient settings is provided. Here 
comparison of group I of DP and group II of GP patients from year 2005 is 
provided. 
3.4.7.1 Description of group II file 
Essential general and analysis data about II group of patients are presented in 

















I. group 113 40 35,4 88 58,8 ±18,76 
II group  1285 42 3,3 71 45,2 ±18,91 
Table 12: Patients settings from both comparing groups-general information (in 
patient’s numbers and %). 
 
From patients data presented we can see marked differences. While in GP set 
were experienced in infection disease 3,3% of patients, in group of DP it was 
even 35,4%.  
Table 13 presents further data regarding prescribed antibiotics according to the 
fact of adherence to recommendations as adherent, reasonable, or non-adherent 
cases. Non-adherence rate in I and II group was 14/88 (15,9%) and 39/71 




Group of patients Adherence Reasonable Non-adherence 
I 
 
Number 32 42 14 
% 36,4 47,7 15,9 
II 
 
Number 5 27 39 
% 7,0 38,0 54,9 
Table 13: Comparison of two different patient settings expressed as rate to 
adherence of rational drug use guidelines (in patient’s numbers and %). 
 
Concerning non-adherence of separate infection diseases, our comparison 
shows that the extend area where was the antibiotics prescribed are different in 
case of respiratory tract infections (RTI), dermatogenic infections, urinary tract 











Group I  43,8 6,3 25,0 25 
Group II 78,6 9,0 1,9 10,5 
Table 14: Spectrum of infection with non-adherence in comparing group I and 
II (in patient’s %). 
 











Group II % 
 
Graph 8: Spectrum of infections with non-adherence in comparing group I and 
II (in patient’s %). 
 
Followed are examples of the most common cases of deviation from 
recommendations. Further examples provide spectrum of inappropriate 
behavior: 
 inappropriate indication (that means the drug product is not being 
properly chosen for desired purpose) 






 For respiratory tract infections were the most often 
prescribed cefuroxime, even it is neither first choice nor 
alternative 
 UTI-the most occurs antibiotic is ciprofloxacin, which 
also not belongs among ones with the first choice 
Inappropriate 
dosage 
 Amoxicillin in too high dosage occur like the most 
frequent problem in this area 
Inappropriate 
duration 
 Concerning duration we lack quite a lot data, but it seems 
UTI is usually treated too short, when is recommended 
not less then 14 days 
Table 15: The most frequently occurring inappropriate drug using. 
 
3.4.7.2 Conclusion of comparison between DP and GP patients 
In summary, comparative data show relatively different rate of non-adherence 
between both settings. Dialysed patient’s population show less extend of non-
adherence comparing to GP population. Larger amount of non-adherence 
shows potential risk for non-rational use of drugs. With majority problems, 
which are in cases of using cefuroxime and amoxicillin and in treatment of 
respiratory tract infections and UTI. 
Data stress on biggest attention to be devoted during intervention in case of 
choice of indication. Moreover, try to utilize the formulary with rational drug 
use. 
3.4.8 Analysis of reasons for non-adherence to guidelines 
33 cases of non-adherence were analysed and recorded into the form.  This is 
described in Attachment 1. In majority of cases, three types of reasons were 
noted. These were: 
1. “Lack of knowledge”; 
2. “Fear for treatment failure”; 
3. “Laboratory tests results were not taken into the consideration”. 
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Main perceived reasons for non-adherence for both years were leaded by “lack 
of knowledge” in 16 cases (48,5%), followed by “laboratory tests results were 
not taken into consideration” in 13 cases (39,4%) and “fear for treatment 




2005(14=100%) 2006(19=100%) 2005&2006 
(33=100%) 
1 42,9 52,6 48,5 
2 14,3 10,5 12,1 
3 42,9 36,8 39,4 
Table 16: Reasons of non-adherence to national guidelines in years 2005 and 
2006 (in patient’s %). 
3.5 Discussion 
3.5.1 General introduction 
Antibiotic treatment and prophylaxis of dialysed patients with the aim to put 
behind consequential complication has its own specificity. To be successful the 
patient has to be motivated to long-term cooperation with the physician and 
dialysis team. One’s own treatment and also its outcomes may be perceived 
from health workers and patients slightly differently. Appreciation mainly 
negatively noticed aspects of illnesses are able to help practitioners better 
established relation based on respect and confidence. Therapeutic tendency are 
than more effective. 
We accomplished investigation in nephrology department in public hospital on 
KMUK (2200 beds) in Lithuania, which mapped how the antibiotics are pres-
cribed. In this area is lack information that’s why we wanted to contribute with 
this thesis into the spectrum of pharmaceutical care. Simultaneously for 
purpose we confront study of Petrikaité V.
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. Limit for this research was 
language barrier in the clinic, but all people who participate to create this work 
were extremely compliant. 
The information’s were collected from medical charts of patients, who attended 
dialysis department.  
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The most of dialysed patients are located in interval 51-70 years, which arise 
from epidemiology of renal replacement therapy, where the biggest portion of 
patients starts to be treated around 55 ages. With increasing age the prevalence 
of dialysis treatment applications raises. 
Twelve nephrologists provide also care beside general practitioners. This 
reality results from fact that patients attend department three times a week.  
Generally, we can say that outcomes of frequency analysis from separately 
years of dialysed patients are not markedly differential. These two groups 
embody high grape of homogeneity from aspect of pharmacotherapy. We can 
judge there is the same level of rationality in pharmaceutical care. Concerning 
patients from GP we found differences between them and nephrology patients. 
Set of GP patient show bigger extent of non-adherence to known guidelines 
and recommendation of appropriate ABT therapy. It arises out of the fact, that 
DP cohort suffer from additional concomitant disease and also larger amount 
of elderly patient are more susceptible to various illness. 
3.5.2 The based characteristics of ABT in monitored set 
Frequency analysis of demographic characteristics of monitored set- age and 
gender of patients-have shown, that in our pursued group are not marked 
differences from cohort of dialysed patients from observed study of clinical 
studies. 
In our set makes the mean age 58,9 years from range 20 to 84 years. Preva-
lence of renal replacement therapy is same both males and females. 
3.5.3 Pharmacotherapy and prophylaxis 
For easier intelligibility of pharmacotherapy and pharmacoprophylaxis of 
monitored patients set was frequency analysis implement according our re-
adjustment. Administered pharmaceuticals were section accordance separately 
case. Term therapy case corresponds with a fact, that for one indication of 
infection disease patient were treated with individual kind of antibiotic. It 
means that for one infection treated period with prescription for instance three 
consecutively antibiotic agents presents three cases. Then can be each case 
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consider separately and more distinctly. However, cases involving one patient 
were discussed and evaluating in a complex way, because it relate together.  
Frequently we can found just incomplete information. The reason why is, that 
the information was handwritten by the physician and often without mentioned 
the dose, dosage, or duration of treatment. 
Clearly we determined that the most of all prescribed antibiotics were amoxi-
cillin 23,4% in a both years and cefuroxime 19,8%. These agents are with a 
wide broad spectrum activity. 
Amoxicillin cover infections of upper and lower respiratory tract, ears 
infection, urogenital tract infection, and dermatogenic infections. Incident of 
infections in dialysed patients appear very often. Dosing has to be decreased on 
250 to 500 milligrams ones time per day. Sometimes this recommendation was 
broken. Overall, this antimicrobial agent is support well by patients.  
Cefuroxime have similar indication for infection like amoxicillin. Special 
utilization of this agent may perform for sequence therapy for instance 
pneumonia, when primarily administration is parenteral and continue with per 
oral delivery. With a dosing less then one gram per day is need no special 
disposal. 
3.5.4 Indication of infection disease 
Procedure for discovery type of infections disease is often accomplished on the 
empirical based. In spite of it we discover moderate improvement in providing 
of microbiological test for detect causative microorganisms. While physicians 
in year 2005 carried out just 20,5% culture test from all 88 therapy cases, in 
year 2006 already 26,6% tests from 109 therapy cases were embrace into the 
consideration. 
Among one of the drug therapy problem we found was use of an inappropriate 
antimicrobial drug. Rare, but still in some cases was prescribed antimicrobial 
drug to which the infecting bacteria are resistant according usual laboratory 
tests. Such usage has been shown to be highly deleterious in terms of cure rate 
in patients with serious infections, but it is noteworthy that even under such 




The patients from our set were the most of all treated for lower respiratory tract 
infections namely 36,5% from all infection diseases and greatest representation 
from this portion belongs to pneumonia. In both years were experienced with 
pneumonia almost one third of all treated patients (precise 27,4%). For this 
illness physicians used mainly cefuroxime (37,0%) and amoxicillin (31,5%). 
Ordinarily for not serious community acquired pneumonia manages peni-
cillin V and G. Thereof we may trace up excessive use of wide broad spectrum 
antibiotic agent. 
On the second place appear urinary tract infections, where can be involve 
asymptomatic bacteriuria, symptomatic cystitis, acute pyelonephritis, emphy-
sematous infections, papillary necrosis candidal infections, and perinephric 
abscess with a different degree of seriousness from mild infection up 
complicated illness. Here ciprofloxacin were prescribed in 30 % of UTI 
infections. This agent not belongs to the first choice but like an alternative drug 
choice. 
In comparison of two different settings of DP and GP patients, noticeable 
difference in number of treated patients was observed in 2005 - 3,3% (GP) 
versus 35,4% (DP). It may origin from higher mean age and bigger amount of 
concomitant disease of dialysed patients. This hypothesis should be tested on 
enlarged set of patients. 
3.5.5 Non-rationality of ABT in our monitored set 
Despite of wide announcement, guidelines have had limited effect on changing 
physician behavior. Their adherence to guidelines may be aggravated by 
variety of barriers. A theoretical approach can help explain these barriers and 
possibly help target interventions to specific impediment.
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Among the relevant errors in KMUK belongs use of an agent with an inappro-
priate spectrum, administration of antibiotics when there is little evidence of 
bacterial infection, unnecessary prolonged courses, and overuse of intravenous 
agents. We could assume that the physicians rather choose antibiotic with a 
broaden spectra to be sure for effectiveness, but thereby increase resistance and 
unneeded overload of the patients. The results are increase side effects for the 
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patients, which we can obviate; spread the resistance to antibiotics for the 
community as a whole and deviation from adherence of guidelines concerning 
rationality use of drugs.
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The process of ensuring that guidelines are introduced into clinical practice is 
necessary for improvements in health care on particular departments. There is 
strong evidence that guidelines are often not adopted.
36
 Survey have shown that 
compliance vary from 20% to >90%
37
, depending on nature of the guideline, 
the specific clinical problem it is designed to address , the patients group being 
targeted, the mode of implementation and the definition of adherence.
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Non-adherence can be considered an issue of behavior, therefore, resolving this 
problem requires a change in behavior, sometimes on the patient’s part (few of 
them prefers not to take or forgets to take medications). But more often the 
non-adherence problems require changes in the part of the health care 
practitioners or the system. All non-adherences have the root cause, and by 
determining why the advancement is not keep, can an effective solution be 
implemented. 
These findings define a strategy for targeted intervention in nephrology setting. 
The records help to improve solving drug therapy problems. Important fact, 
that this area start to be mapped and we can arrange next steps to improve 
adherence to recommendation, when is still necessary to pursued the health 
practitioners to followed and used appropriate guidelines. Also ascertain that 
these practitioners, who intend to provide pharmaceutical care, understand the 
descriptions and identification of emerged drug therapy problem as well as 
their causes. As general rule, whenever possible appropriate clinical specimen 
should be obtained to attempt a culture-proven diagnosis so that the most effec-
tive antibiotics can be selected for targeted therapy and for correct duration. 
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4 CONCLUSION 
In my diploma thesis I tried to illustrate the difficulties encountered when 
measuring the impact of interventions to promote the rational use of antibiotics. 
Nevertheless, I suggest a positive effect of the development and implemen-
tation of national guidelines in nephrology department, particularly when it 
would be reinforced by a clinical pharmacist. 
 
From our survey, emerge subsequent results: 
1. 35% (in 2005) to 45% (in 2006) of DP population annually are 
suffering form infectious diseases (mainly pneumonia and UTI) and are 
treated mainly with amoxicillin (in 23,4% of cases), cefuroxime 
(19,8%), and/or ciprofloxacin (12,7%) most often during 6 to 10 days 
of treatment. 
2. Non-adherence to nationally available guidelines on rational antibio-
ticotherapy in DP population was observed in 15,9% (in 2005) and 
17,4% (in 2006) of ABT cases. Availability of bacteriological tests for 
indication of illness was provided in 20,5% (in 2005) and 26,6% (in 
2006). 
3. Main perceived reasons for non-adherence were the “lack of 
knowledge” in 16 cases (48,5%), followed by “laboratory tests results 
were not taken into consideration” in 13 cases (39,4%) and “fear for 
treatment failure” in 4 cases (12,1%) and for both years. 
4. In comparison of two different settings of DP and GP patients there was 
observed noticeable difference in number of treated patients during year 
2005 (3,3% in GP vs 35,4% in DP population) and incidents of non-




ABT   Antibioticotherapy 
A-V   Arterio-venous 
CAPD  Continuous ambulatory peritoneal dialysis 
CMP   Cardiomyopathia 
CNS   Central nervous system 
CrCl   Creatinine clearance 
CRF   Chronic Renal Failure 
CRP   C-reactive protein 
D I, II   Diabetes mellitus type I, II 
DP   Dialysed patients 
ESRF   End-stage renal failure 
GFR   Glomerular filtration rate 
GI   Gastrointestinal tract 
GNCH  Glomerulonephritis chronica  
GP   General practitioner 
HP   Hyperplasia prostate 
HPTD   Hyper­para­thyroidism 
i.v.   Intra venous 
INRUD  The International Net­work for the Rational Use of Drug  
K%   Constant for elimination  
KMUK  Clinics of Kaunas Medical University  
MDRD  Modification of diet in renal disease formula to calculate GFR 
NA   Non-adherence 
No (N)  number 
ORL   Otorhinolaryngology 
p.o.   Per os 
Pg  Page 
PD   Peritoneal dialysis 
PCH  Chronic pyelonephritis 
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PTH   Parathyroid hormone 
RRT   Renal Replacement Therapy 
RTI   Respiratory tract infections 
UTI   Urinary tract infections 
vs   Versus 
WBC   White blood cells 




Attachment 1: Form paper summarizing all available data about treatment of 




For each patient being treated with antimicrobial drugs 
 
Patient’s name: 
Patient’s identification number: 
 
Start of collection the information’s: 
Name of a physician: 
 
Gender (male / female) 
Age: 
Weight: 





History of medicament use: See Pg.4 
 
I Antimicrobial drugs 
 






Dosage form Aim of treatment 
p.o. i.v. Treatment Prophylaxis 
Antibiotics 
       
       
       
Type of infection: 
 
Start of antibiotic therapy  <1 day  1-2 days Longer:  
 
Duration of antimicrobial therapy: ... 
Source of the antibiotic:  hospital  pharmacy 
 private  other 
If the therapy is prophylaxis 
Surgical:  
Type of operation 
Was any injection during the operation? YES NO 





If the therapy is treatment 
Do the choice of antibiotic comply to the medical record  YES NO 
 
 Acquired infections 
Public From hospital or <48 
hour after stationary 
Types of infection(s), plz show precisely in case of more than one disease. 
Sepsis   
Upper resp. tract infection   
Lower resp. tract infection   
Urinary tract infection   
Infection due to wound 
after operation 
  




Osteomyelitis   
CNS infection   
Gynaecological infection   
A-V fistula infection   
Dermatogenic and mucous 
infection 
  
Eye infection   
Other   
Not clear at all   
 
II. Indication for treatment 
 
Culture and sensitivity was made: 
 If yes,  
From where the investigation materials were taken: 
The results of laboratory tests must show to what it is sensitive: 
Resistance to what: 
            If not,  
Reason(s): 





 If empirical, was quick bacterioskopic diagnosis performed? YES/NO 
 If yes, 
                    Investigation materials taken: 
                    Results of the tests: 
 
 If not, 
                    Why? 
                     Other reason: 
 
Localization diagnosis of the infection have been confirmed objectively 
 YES NO  
(Show objective information) 
 
 
  III Risk factors for hospital infections  
 
YES NO known 
Urinary bladder catheter   
Central vein catheter 
Diabetis mellitus 
Artificial lung ventillation 







  IV Evaluation of rational antimicrobial therapy 
 
The antimicrobial drug therapy does satisfy the rational drug therapy 
recommendation. 
The antimicrobial drug therapy does not satisfy the rational drug therapy 
recommendation. 
 






Date:   
Drug 
name 




 Culture and sensitivity was made: 













Localization diagnosis of the 
































IV Evaluation of rational 
antimicrobial therapy: Pg2 
does satisfy 
does not satisfy 
Does the doctor know about the 




















Improved:                 
Constant: 




  V. Reason why antibiotics are prescribed not rationally 
 
          
 YES  NO 
1. Lack of knowledge in antibiotics. 
2. Fear of treatment failure. 
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